Amphotericin B Liposomal Dosage
Medically reviewed by Drugs.com. Last updated on Feb 17, 2025.
Applies to the following strengths: 50 mg
Usual Adult Dose for:
- Aspergillosis - Invasive
- Candidemia
- Cryptococcosis
- Febrile Neutropenia
- Cryptococcal Meningitis - Immunosuppressed Host
- Leishmaniasis
- Coccidioidomycosis
- Blastomycosis
Usual Pediatric Dose for:
- Aspergillosis - Invasive
- Candidemia
- Cryptococcosis
- Febrile Neutropenia
- Cryptococcal Meningitis - Immunosuppressed Host
- Leishmaniasis
Additional dosage information:
Usual Adult Dose for Aspergillosis - Invasive
3 to 5 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.
Usual Adult Dose for Candidemia
3 to 5 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.
Usual Adult Dose for Cryptococcosis
3 to 5 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.
Usual Adult Dose for Febrile Neutropenia
3 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Use: Empiric therapy for presumed fungal infection in febrile, neutropenic patients.
Usual Adult Dose for Cryptococcal Meningitis - Immunosuppressed Host
6 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Use: Treatment of Cryptococcal meningitis in HIV infected patients
Usual Adult Dose for Leishmaniasis
Immunocompetent patients: 3 mg/kg/day IV on days 1 through 5, and days 14 and 21
- Infuse over 120 minutes.
- If parasitic clearance is not achieved, a repeat course may be useful.
Immunocompromised patients: 4 mg/kg/day IV on days 1 through 5, and days 10, 17, 24, 31 and 38
- Infuse over 120 minutes.
- If parasitic clearance is not achieved or relapse occurs, seek expert advice regarding further treatment.
Comments:
- Relapse rates after initial clearance of parasites were high in immunocompromised patients treated with this drug.
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Use: Treatment of visceral leishmaniasis
Usual Adult Dose for Coccidioidomycosis
Severe, non-meningeal infection: 3 to 5 mg/kg/day IV
Duration of therapy: Until clinical improvement
- Follow with triazole
Use: Coccidioidomycosis
Usual Adult Dose for Blastomycosis
Moderate to severe pulmonary blastomycosis: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted
- Follow with itraconazole
Moderate to severe extrapulmonary blastomycosis: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted
- Follow with itraconazole
CNS blastomycosis: 5 mg/kg/day IV
Duration of therapy: 4 to 6 weeks
- Follow with an oral azole
Blastomycosis, immunosuppressed patient: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted
- Follow with itraconazole
Blastomycosis during pregnancy: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted
- Avoid azoles because of possible teratogenicity
Use: Blastomycosis
Usual Pediatric Dose for Aspergillosis - Invasive
1 month and older:
3 to 5 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.
Usual Pediatric Dose for Candidemia
1 month and older:
3 to 5 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.
Usual Pediatric Dose for Cryptococcosis
1 month and older:
3 to 5 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.
Usual Pediatric Dose for Febrile Neutropenia
1 month or older:
3 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Use: Empiric therapy for presumed fungal infection in febrile, neutropenic patients.
Usual Pediatric Dose for Cryptococcal Meningitis - Immunosuppressed Host
1 month or older:
6 mg/kg/day IV over 120 minutes
Comments:
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Use: Treatment of Cryptococcal meningitis in HIV infected patients
Usual Pediatric Dose for Leishmaniasis
1 month or older:
Immunocompetent patients: 3 mg/kg/day IV on days 1 through 5, and days 14 and 21
- Infuse over 120 minutes.
- If parasitic clearance is not achieved, a repeat course may be useful.
Immunocompromised patients: 4 mg/kg/day IV on days 1 through 5, and days 10, 17, 24, 31 and 38
- Infuse over 120 minutes.
- If parasitic clearance is not achieved or relapse occurs, seek expert advice regarding further treatment.
Comments:
- Relapse rates after initial clearance of parasites were high in immunocompromised patients treated with this drug.
- Individualize dosing and rate of infusion to ensure maximum efficacy and minimize toxicities or adverse events.
Use: Treatment of visceral leishmaniasis
Renal Dose Adjustments
Data not available
- This drug has been successfully administered to patients with pre-existing renal impairment.
Liver Dose Adjustments
Data not available
Precautions
Safety and efficacy have not been established in patients younger than 1 month.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
- Hemodialysis or peritoneal dialysis do not appear to significantly affect elimination of this drug.
Other Comments
Administration advice:
- Administer over approximately 120 minutes using a controlled infusion device.
- Administration time can be reduced to 60 minutes if treatment is well tolerated.
- Administration time can be increased if the patient experiences discomfort.
- An inline filter may be used if mean pore diameter is not less than 1 micron.
- Existing IV line must be flushed with 5% dextrose prior to administration; if line cannot be flushed with 5% dextrose, administer through a separate line.
Storage requirements:
- Store at temperatures up to 77F.
Reconstitution/preparation techniques:
- The manufacturer product information should be consulted.
IV compatibility:
- Dilute with 5% dextrose.
- Not compatible with saline.
- Do not mix with other drugs.
General:
- Carefully observe patients during the initial dosing period.
More about amphotericin b liposomal
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- During pregnancy
- Drug class: polyenes
- En español
Patient resources
Other brands
Related treatment guides
See also:
Augmentin
Augmentin is a prescription antibiotic combining amoxicillin and clavulanate to treat bacterial ...
Diflucan
Diflucan (fluconazole) is used to treat and prevent fungal infections. Includes Diflucan side ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Zosyn
Zosyn is used to treat bacterial infections such as urinary tract and skin infections and ...
Posaconazole
Posaconazole systemic is used for aspergillosis, invasive, candidemia, oral thrush
Voriconazole
Voriconazole systemic is used for aspergillosis, invasive, blastomycosis, candidemia ...
Itraconazole
Itraconazole systemic is used for aspergillosis, aspergilloma, aspergillosis, invasive ...
Piperacillin/tazobactam
Piperacillin/tazobactam systemic is used for appendectomy, appendicitis, aspiration pneumonia ...
Gentamicin
Gentamicin systemic is used for bacteremia, bacterial endocarditis prevention, bacterial infection ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.